Aryanpour Narges, Farnam Golrokh, Behtaj Reyhaneh, H Shirazi Farshad
Pharmaceutical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Toxicology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Iran J Pharm Res. 2022 Feb 16;21(1):e123823. doi: 10.5812/ijpr.123823. eCollection 2022 Dec.
Breast cancer is a heterogeneous disease in which many factors and receptors are effective in the disease process and response to treatment. Currently, estrogen, progesterone, and HER2 receptors are among the most important factors in choosing a treatment regimen. Other metabolic factors that may affect the treatment outcome include diabetes and hyperinsulinemia. In order to evaluate the role and complexity of cross-talk between different pathways initiating from various receptors, value the most common drugs in the treatment of breast cancer are investigated on different cell lines in this manuscript at the cell culture level. The result of different doses of Tamoxifen and estradiol on the cells with various levels of the estrogenic, progesterone, and HER2 receptors is examined alone, or in combinations, and the presence or absence of insulin. The effects of these variables on the cells' growth pattern and survival in various breast cancer cells are investigated using cell counting, colony counting, and MTT assays. Our results have further confirmed the complexity of deciding on the outcome of treatment for breast cancer with such a wide variability in the kind of receptors and biochemical agents present in the body of a cancer patient.
乳腺癌是一种异质性疾病,其中许多因素和受体在疾病进程及对治疗的反应中发挥作用。目前,雌激素、孕激素和HER2受体是选择治疗方案时最重要的因素。其他可能影响治疗结果的代谢因素包括糖尿病和高胰岛素血症。为了评估源自各种受体的不同信号通路之间相互作用的作用及复杂性,本文在细胞培养水平上,研究了乳腺癌治疗中最常用药物对不同细胞系的影响。单独或联合检测不同剂量他莫昔芬和雌二醇对具有不同雌激素、孕激素和HER2受体水平的细胞的作用,以及胰岛素的存在与否。使用细胞计数、集落计数和MTT试验研究这些变量对各种乳腺癌细胞的细胞生长模式和存活的影响。我们的结果进一步证实了,鉴于癌症患者体内受体种类和生化因子存在如此广泛的变异性,决定乳腺癌治疗结果具有复杂性。